KRAS and neoplasm: Mutated KRAS in combination with inflammation or loss of key tumor suppressors drives progression of pre-malignant lesions to PDAC and is implicated in the recruitment of an immunosuppressive cellular milieu through KRAS-driven production of pro-inflammatory cytokines and chemokines [60,61,62,63].